Diagnostic Center | December 15, 2022
Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The investment will enable the company to enter European markets as well as enhance margins in current markets
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
More women centric initiatives being the need of the hour for holistic development
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
Subscribe To Our Newsletter & Stay Updated
